Clinical trials: Paclitaxel
Carcinoma, Non-Small-Cell Lung
A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer
Successful treatment of lung cancer with radiation therapy requires that the physicians determine exactly where the tumor is in the patient's body and seek to limit any unnecessary radiation to normal parts of the body.
- Trial name
- NCT02492867
- Testing
- Response-driven Adaptive Radiation Therapy, Carboplatin, Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- University of Michigan Rogel Cancer Center
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer
This partially randomized phase Ib/II trial studies the side effects and best dose of selinexor when given together with gemcitabine and nab-paclitaxel, and to see how well they work in treating patients with pancreatic cancer…
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage IV Pancreatic Cancer
- Trial name
- NCT02178436
- Testing
- gemcitabine hydrochloride, Selinexor, Pharmacological Study
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Mohammed Najeeb Al Hallak
Non-small Cell Lung Cancer
Concurrent Endostar, Paclitaxel/Carboplatin and Radiotherapy for Locally Advanced Non-small Cell Lung (RT0902)
Concomitant chemoradiotherapy is the standard treatment of locally advanced, non-resectable, non-small cell lung cancer (NSCLC). However, the optimal chemotherapy regimen is still controversial.
- Trial name
- NCT01158144
- Testing
- Endostar, Paclitaxel/Carboplatin
- Where
- 2 sites in China
- Volunteers
- 134 people
- Sponsor
- Zhejiang Cancer Hospital
Head and Neck Squamous Cell Carcinoma
FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma
The goal of this FID-007 Clinical Trial is to compare the efficacy of different dosing regimens of FID-007 in combination with Cetuximab in patients with recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).
- Trial name
- HNSCC (NCT06332092)
- Testing
- FID007
- Where
- 6 sites in United States
- Volunteers
- 46 people
- Sponsor
- Fulgent Pharma LLC.
Cervical Cancer
Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and IIA2 Cervical Cancer Followed by Radical Hysterectomy
The purpose was to establish a quick (7-day) cycle schedule of paclitaxel (60 mg/m2) combining with cisplatin (40 mg/m2) NAC regimen could be tolerated without interfering the following surgical treatment and a favorable overall…
- Trial name
- NCT02432365
- Testing
- paclitaxel, cisplatin, Radical hysterectomy and bilateral pelvic lymphadenectomy
- Where
- 5 sites in Taiwan
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Neoplasms, Carcinoma, Squamous
Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma
This is a single-arm, open, II phase study to evaluate the safety and efficacy of Nivolumab + carboplatin + paclitaxel in 25 newly diagnosed patients with primary tracheal squamous cell carcinoma.
- Conditions
- Neoplasms, Carcinoma, Squamous, Antineoplastic Agents
- Trial name
- GALAXY-1 (NCT05964101)
- Testing
- Nivolumab Injection [Opdivo]
- Where
- China
- Volunteers
- 25 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Esophageal Cancer
Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002711
- Testing
- chemotherapy, cisplatin, paclitaxel
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Non-Small Cell Lung Cancer
Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)
The primary hypothesis is that pembrolizumab/vibostolimab (MK-7684A) in combination with chemotherapy is superior to pembrolizumab in combination with chemotherapy with respect to overall survival (OS) in participants with…
- Trial name
- NCT05226598
- Testing
- Pembrolizumab/Vibostolimab, Carboplatin, Cisplatin
- Where
- 149 sites in United States, Argentina and 17 more
- Volunteers
- 739 people
- Sponsor
- Merck Sharp & Dohme LLC
Germ Cell Tumor, Yolk Sac Tumor
Clinical Study of Chemotherapy in the Treatment of Recurrent/Refractory Yolk Sac Tumor in Children
Remarkable progress has been made in treating germ-cell tumor (GCT) through the use of platinum-based regimens. However, part of yolk sac tumor (YST) with cisplatin resistance or recurrence is nevertheless prone to relapse after…
- Trial name
- SCRRYST (NCT06341998)
- Testing
- sirolimus combined with chemotherapy in the treatment of recurrent/refractory yolk sac tumor in children
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Shandong First Medical University
Oropharyngeal Cancer
Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer
This is a single-center phase 2 study of to test how well the combination of toripalimab with chemotherapy followed by TORS or risk and response stratified de-escalated (chemo)radiotherapy works in patients with in HPV16+…
- Trial name
- NCT07290621
- Testing
- Toripalimab, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Chicago
Non-small Cell Lung Cancer
mil60 Versus Bevacizumab in Patients With Treatment-naïve Non-squamous Non-small Cell Lung Cancer
This randomized, double-blind, multi-center phase 3 study is aimed to compare the efficacy and safety of mil60 with bevacizumab as first-line treatment when combined with standard chemotherapy (paclitaxel/carboplatin) in…
- Trial name
- NCT03196986
- Testing
- mil60, Bevacizumab
- Where
- 2 sites in China
- Volunteers
- 517 people
- Sponsor
- Beijing Mabworks Biotech Co., Ltd.
Cancer
Chemoradiation +Gemcitabine +Continuous 5-FU (Fluorouracil) Followed by High Dose Brachytherapy/Stereotactic Radiation Boost in Locally Advanced Intra/Extrahepatic Cholangiocarcinoma
OBJECTIVES: This study proposes to evaluate the feasibility of delivery of this treatment in terms of toxicity. If toxicity is not acceptable, the treatment is not feasible.
- Trial name
- NCT00983541
- Testing
- Fluorouracil (5-FU), Brachytherapy or SBRT (Stereotactic body radiation therapy), Gemcitabine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Utah
Endometrial Cancer
Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer
The primary objective of this study is to estimate whether the addition of trastuzumab to paclitaxel and carboplatin chemotherapy improves progression free survival when compared to paclitaxel and carboplatin alone in Uterine…
- Trial name
- NCT01367002
- Testing
- Carboplatin/Paclitaxel, Trastuzumab
- Where
- 20 sites in United States
- Volunteers
- 61 people
- Sponsor
- Yale University
Esophageal Squamous Cell Carcinoma
Paclitaxel or S1 Plus Cisplatin in Concurrent Chemoradiotherapy for Squamous Cell Carcinoma of Esophagus
The purpose of this study is to determine which regimen is better for esophageal squamous carcinoma in concurrent chemoradiation(CCRT),paclitaxel or S1 plus cisplatin.
- Trial name
- NCT02586753
- Testing
- Paclitaxel plus Cisplatin with radiotherapy, S1 plus Cisplatin with radiotherapy
- Volunteers
- 2 people
- Sponsor
- Mianyang Central Hospital
Multiple Myeloma, Triple Negative Breast Cancer
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
This study is comprised of a main study, an observational study, and optional survey studies. The main study is being done to see whether using Duffy null specific treatment dosing guidelines can reduce or delay dose…
- Conditions
- Multiple Myeloma, Triple Negative Breast Cancer, Duffy Blood Group, Chemokine Receptor Gene Mutation, Duffy Blood Group, Chemokine Receptor Gene C.-67T>C
- Trial name
- NCT07341867
- Testing
- Dexamethasone, Bortezomib, LENALIDOMIDE
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Andrew Hantel, MD
Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
The goal of this clinical study is to see if sacituzumab govitecan-hziy (SG) can improve life spans of people with HR+/HER2- metastatic breast cancer and their tumor does not grow or spread when compared to currently available…
- Trial name
- ASCENT-07 (NCT05840211)
- Testing
- Sacituzumab Govitecan-hziy, Paclitaxel, Nab-paclitaxel
- Where
- 288 sites in United States, Argentina and 26 more
- Volunteers
- 654 people
- Sponsor
- Gilead Sciences
Esophageal Neoplasms
Addition of Enoxaparin to Neoadjuvant Chemoradiation of Esophageal Cancer
This is a randomized, single blind, multi-center, phase two clinical trial. Inclusion criteria are consist of non-metastatic esophageal cancer who are going to receive chemo-radiotherapy.
- Trial name
- NCT03254511
- Testing
- Enoxaparin Sodium 40 MG/0.2 ML Subcutaneous Injectable, Radiotherapy, Chemotherapeutic Combinations
- Where
- Iran
- Volunteers
- 100 people
- Sponsor
- Mashhad University of Medical Sciences
Squamous Cell Carcinoma, Adenocarcinoma
Chemoradiation and Panitumumab for Esophageal Cancer
A consistent finding in many studies in patients with operable esophageal and gastro-esophageal junction (GEJ) cancer is that response to preoperative therapy, particularly the absence of residual disease in the surgical…
- Conditions
- Squamous Cell Carcinoma, Adenocarcinoma, Esophageal Cancer, Gastro-esophageal Junction Cancer
- Trial name
- NCT01077999
- Testing
- Carboplatin, Paclitaxel, panitumumab
- Where
- Netherlands
- Volunteers
- 78 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Carcinoma, Non-Small-Cell Lung
A Dose Escalation Study of BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung Cancer
The primary objectives of this trial were to determine the MTD of BIBF 1120 in combination with carboplatin and paclitaxel, pharmacokinetics and objective response of treatment
- Trial name
- NCT02182232
- Testing
- BIBF 1120, Paclitaxel, Carboplatin
- Volunteers
- 33 people
- Sponsor
- Boehringer Ingelheim
Triple Negative Breast Cancer(TNBC)
PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC
This multicenter, randomized, double-blind study will evaluate the safety and efficacy of PM8002 in combination with Nab-Paclitaxel compared with placebo combined with Nab-Paclitaxel as first-line treatment in inoperable locally…
- Trial name
- NCT06419621
- Testing
- PM8002, Nab-Paclitaxel
- Where
- 70 sites in China
- Volunteers
- 392 people
- Sponsor
- Biotheus Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.